{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen Z"],"funding":["National Natural Science Foundation of China"],"pagination":["55-69"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10686145"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1(1)"],"pubmed_abstract":["<h4>Background</h4>Limited by difficulties in early detection and availabilities of effective treatments, pancreatic cancer is a highly malignant disease with poor prognosis. Nuclear receptors are a family of ligand-dependent transcription factors that are highly druggable therapeutic targets playing critical roles in human physiological and pathological development, including cancer. In this study, we explored the therapeutic potential as well as the molecular mechanisms of liver X receptor (LXR) agonist GW3965 in pancreatic cancer.<h4>Methods</h4>Soft-agar colony formation assay, xenograft tumors, Oligonucleotide microarray, Reverse transcription real-time polymerase chain reaction, Western immunoblotting and Immunohistochemistry were used in this study.<h4>Results</h4>We demonstrated pl"],"journal":["Cancer innovation"],"pubmed_title":["ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activities of liver X receptor in pancreatic cancers."],"pmcid":["PMC10686145"],"funding_grant_id":["81472692","81270868","81573012"],"pubmed_authors":["Lai X","Xia X","Ding H","Chen Z","Chiao PJ","Ling J","Sun Y","Zhang A"],"additional_accession":[]},"is_claimable":false,"name":"ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activities of liver X receptor in pancreatic cancers.","description":"<h4>Background</h4>Limited by difficulties in early detection and availabilities of effective treatments, pancreatic cancer is a highly malignant disease with poor prognosis. Nuclear receptors are a family of ligand-dependent transcription factors that are highly druggable therapeutic targets playing critical roles in human physiological and pathological development, including cancer. In this study, we explored the therapeutic potential as well as the molecular mechanisms of liver X receptor (LXR) agonist GW3965 in pancreatic cancer.<h4>Methods</h4>Soft-agar colony formation assay, xenograft tumors, Oligonucleotide microarray, Reverse transcription real-time polymerase chain reaction, Western immunoblotting and Immunohistochemistry were used in this study.<h4>Results</h4>We demonstrated pl","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-07-14T22:01:56.708Z","creation":"2025-04-19T04:09:48.465Z"},"accession":"S-EPMC10686145","cross_references":{"pubmed":["38089448"],"doi":["10.1002/cai2.12"]}}